Technology Review - Published By MIT
Advertisement

Using Molecular Pathways to Assess Cancer Patients

The first complete map of protein interactions in human cells could lead to better treatment for breast cancer.

By Katherine Bourzac

Wednesday, October 17, 2007

smaller text tool iconmedium text tool iconlarger text tool icon

Researchers at the University of California, San Diego, have created a map of all known protein networks in human cells and shown that it can be used to better assess whether a patient's breast cancer will spread. Their work, though in its early stages, could lead to better diagnostic tests that spare patients toxic treatments, such as chemotherapy, if they are unnecessary. The researchers also expect that their approach will be widely applicable to other diseases, including other cancers and diabetes.

Pathways to cancer: Pictured above are two protein networks whose activity is associated with an increased risk of the spread of breast cancer. At top is a protein network associated with cell growth, survival, and division; at bottom, a protein network associated with tumors’ ability to shape surrounding tissue.
Credit: Trey Ideker, UCSD

The current standard for assessing how to treat breast-cancer tumors involves clinical diagnosis and gene-expression profiling tests. But it has been difficult to predict how aggressive a cancer will be using this method.

"We decided to look at breast cancer because it's a very difficult problem in terms of prognosis," says Trey Ideker, the bioengineer who led the construction of the protein map.

He notes that even the best diagnostic chips for the disease have only between 60 and 70 percent accuracy. "Maybe the reason why it's hard to predict the course of metastasis is that it's never caused by the same gene or set of genes," says Ideker. (Metastasis is the spread of a cancer from its original site throughout the body--in the case of breast cancer, often to the lungs or bones.)

"Individual cancers are pretty unique" in terms of which genes contribute to disease, says Julie Gralow, an oncologist and associate professor of medicine at the University of Washington. Metastasis in one patient might be caused by gene A, while in two other patients it's caused by gene B or C.

"There are many routes to cancer," says Ideker. "Maybe the rule is that genes A, B, and C are in the same pathway. The main idea is that we shouldn't be looking for individual genes but at whole processes with multiple genes and proteins tied together in networks."

Story continues below


Finding these pathways or networks in cancer and other diseases is not a new idea. For years, researchers have speculated that detecting changes in molecular pathways--not just in individual genes--could provide more accurate diagnoses and better predictions of the course of complex diseases such as cancer. But James Collins, a biomedical engineer at Boston University, notes that "Ideker is the first to figure out how to do it."

Ideker's group pooled decades of research about proteins "to get huge wiring diagrams" that map out how all proteins in the human cell physically interact with each other. The map connects 11,203 proteins (which are visually represented by spheres) through 57,235 interactions (which are represented by lines drawn between the spheres). Ideker likens the tangled network to a hairball.

Comments

  • mRNA abundance does not always equal protein abundance!
    If the "gene-expression profile" from the cancer patient's biopsy means using a microarray to measure the mRNA transcript abundance, it is important to note that the following sentence is scientifically incorrect:

    "They then looked for clusters in the interaction map where the activity level of a group of connected proteins was different in patients whose cancer eventually metastasized than in patients whose cancer did not."

    **mRNA transcript abundance does not equal protein abundance.  There is a 0.5-0.6 correlation (where 1.0 is a perfect correlation) between mRNA abundance and protein abundance for ~1/3 of the yeast genome.  This comparison has not been done for higher eukaryotes on a genome-wide scale. 

    **Just because a patient has higher levels of a particular mRNA transcript in their tumor biopsy sample does NOT mean that they are making more of that particular protein or that they have higher activity levels of that particular protein.  In fact, if we extrapolate from the yeast data, we would conclude that a patient with higher levels of a particular mRNA transcript would also have higher levels of that protein ONLY 50-60% OF THE TIME. 
    Rate this comment: 12345

    dmklass
    10/21/2007
    Posts:2

Log In

Forgot your password?     Register »
Advertisement

Videos

Malleable Maps, Artistic Robots and Bubble Interfaces
Technology Review January/February 2010

Current Issue

Security in the Ether
Information technology's next grand challenge will be to secure the cloud--and prove we can trust it.
Advertisement
Advertisement
Advertisement
Subscribe to Technology Review's daily e-mail update. Enter your e-mail address

TECHNOLOGY RESOURCES

More Technology News from Forbes

Advertisement
MIT Massachusetts Institute of Technology © 2010 Technology Review. All Rights Reserved.